SPORE in Prostate Cancer

前列腺癌中的孢子

• 批准号: 8926374
• 负责人: ARUL M CHINNAIYAN
• 金额: $ 218.5万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-11 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8926374
• 关键词: Biological Markers; Biometry; Bone Pain; Bromodomain; Cancer Patient; Clinic; Clinical; Clinical Investigator; Clinical Management; Cohort Studies; Collaborations; Communities; Complement; Complex; DNA Damage; Data; Detection; Development; Diagnosis; Diagnostic; Early Detection Research Network; Ensure; Epigenetic Process; Extramural Activities; Fostering; Funding; Gene Fusion; Genes; Genetic; Germ-Line Mutation; Goals; Grant; Health; Individual; Industry; Informatics; Institution; Laboratories; Malignant Neoplasms; Malignant neoplasm of prostate; Mentors; Metastatic Neoplasm to the Bone; Michigan; Molecular; Morbidity - disease rate; Nature; Pilot Projects; Prevention; Prostate; Randomized; Recording of previous events; Recruitment Activity; Recurrence; Research; Research Infrastructure; Research Personnel; Resistance; Resources; Risk; Science; Scientist; Side; Southwest Oncology Group; Staging; Sum; Testing; Tissues; Training; Translational Research; Translations; Universities; Untranslated RNA; Urine; anticancer research; base; bench to bedside; cancer cell; cancer risk; career development; castration resistant prostate cancer; clinical efficacy; clinical sequencing; flexibility; improved; inhibitor/antagonist; innovation; men; mortality; multidisciplinary; next generation; novel; phase II trial; precision medicine; precision oncology; prognostic; programs; success; therapy resistant

DESCRIPTION (provided by applicant): Since inception in 1995, the University of Michigan (UIVI) Prostate SPORE has endeavored to tap the vast intellectual and physical resources of the UM community to decrease the morbidity and mortality of prostate cancer (PCa). The UIVI Prostate SPORE supports an interactive group of basic and clinical investigators in a translational research program that has led to major discoveries in the diagnosis, prevention and treatment of prostate cancer. Successful translation of discoveries in the most recent grant period include: 1) development of a urine test for prostate cancer which is now offered in CLIA reference laboratories (Sci TransI Med. 2011); 2) ETS gene fusion driven PCa that are susceptible to PARP inhibitor therapy (Cancer Cell 2011) which initiated a randomized Phase II trial (NCTOI576172); 3) germline mutations in HOXB 13 gene that conferred increased risk for PCa (N Engl J Med. 2012). This is being developed as a test for assessing PCa risk; 4) the first study describing the mutational landscape of metastatic castrate resistant prostate cancer (CRPC) (Nature 2012,) and; 5) Cabozantinib was shown to have efficacy and decrease bone pain in prostate cancer patients with bone metastasis (J Clin Oncol. 2013). These bench-to-bedside applications were aided by horizontal collaborations with the Dana Farber, Baylor, Mayo Clinic and Johns Hopkins Prostate SPOREs as well as the EDRN and vertical collaborations with SWOG and biotech companies. This application consists of four multidisciplinary projects: Project 1: A Precision Medicine Approach to Elucidate Mechanisms of Progression and Resistance to Therapy in Advanced PCa; Project 2: Mechanisms of Sensitivity and Resistance to Cabozantinib in CRPC; Project 3: Development of Novel BET Bromodomain Inhibitors for the Treatment of Advanced PCa; Project 4: Development of IncRNAs as PCa Biomarkers in Urine. These projects are complemented by ongoing, successful Career Development and Developmental Research Programs. The projects and programs are supported by a strong ongoing institutional commitment of money and space as well as three cores: Administration, Biostatistics, and Tissue/Informatics. The UM Prostate SPORE program continues to place premiums on rigorous scientific review of its translational research programs, pairing of basic and clinical investigators, drawing on expertise of scientists from within and fro outside the prostate cancer field, and utilizing flexibility to fund promising new research approaches. The interaction of our multidisciplinary group of investigators clearly makes the Prostate SPORE program at the UMCCC is greater than the sum of its individual parts.

描述(由申请人提供)：自1995年成立以来，密歇根大学(UIVI)前列腺癌孢子一直致力于挖掘密歇根大学前列腺癌(Pca)社区巨大的智力和体力资源，以降低前列腺癌(PCa)的发病率和死亡率。UIVI前列腺孢子支持一项转化研究计划中的基础和临床研究人员的互动小组，该计划在前列腺癌的诊断、预防和治疗方面取得了重大发现。在最近的赠款期间成功转化的发现包括：1)开发前列腺癌的尿液测试，目前CLIA参考实验室(Sci Transi Med)提供这种测试。2)ETS基因融合导致对PARP抑制剂治疗敏感的PCa(癌症细胞2011)，该研究启动了一项随机II期试验(NCTOI576172)；3)HOXB 13基因的胚系突变增加了PCa的风险(N Engl J Med)。2012年)。这是作为一种评估前列腺癌风险的测试而开发的；4)描述转移性去势耐药前列腺癌(CRPC)突变格局的第一项研究(自然，2012)和5)Cabozantinib被证明在前列腺癌伴骨转移的患者中具有疗效和减轻骨疼痛(J Clin Onol)。2013年)。这些从床到床的应用程序得益于与Dana Farber、Bayeller、Mayo Clinic和Johns Hopkins前列腺孢子公司的横向合作，以及EDRN和与SWOG和生物技术公司的纵向合作。这项申请由四个多学科项目组成：项目1：阐明晚期前列腺癌进展和耐药机制的精准医学方法；项目2：CRPC对卡波赞替尼的敏感性和耐药性机制；项目3：开发用于治疗晚期前列腺癌的新型BET溴域抑制剂；项目4：开发IncRNAs作为尿中前列腺癌的生物标记物。这些项目与持续、成功的职业发展和发展研究计划相辅相成。这些项目和计划得到了持续不断的资金和空间以及三个核心的机构承诺的支持：行政管理、生物统计学和组织/信息学。密歇根州立大学前列腺癌孢子计划继续对其翻译研究计划进行严格的科学审查，将基础和临床研究人员配对，利用前列腺癌领域内外科学家的专业知识，并利用灵活性为有前景的新研究方法提供资金。我们的多学科研究小组的互动显然使UMCCC的前列腺孢子计划大于其各个部分的总和。